Uloric

Despite multiple attempts; Takeda still manages to keep Uloric on the market

Leave a Comment / Defective Drugs, Uloric / By Elena Borrelli

This page features: Cited Research Articles Uloric, the common brand name for the medication Febuxostat, manufactured by Takeda Pharmaceuticals, entered the US market in 2009. Uloric is a pill that is advertised to manage gout, a condition that approximately 8.3 million people in the United States suffer from. Gout is a type of arthritis that causes …

Despite multiple attempts; Takeda still manages to keep Uloric on the market Read More »

FDA Issues Safety Warning Due to Increased Death Rates From Febuxostat

Leave a Comment / Defective Drugs, Feature Reports, News, Uloric / By Eric Ridenour

This page features: Cited Research Articles In February of 2019, the FDA issued a new black box warning for the medication febuxostat, which users currently take for gout. The warning states that patients who take the drug are at an increased risk of death due to heart related complications. A recent report showed 15 recent deaths …

FDA Issues Safety Warning Due to Increased Death Rates From Febuxostat Read More »

CONTACT CENTER

Address: 6 Harbor Park Drive Port Washington, New York 11050

Phone: 1-800-320-8000

Email: Info@Drugreport.com

NAVIGATION

OUR MISSION

DrugReport’s mission is to investigate the truth about pharmaceutical drugs and medical devices that have harmed people, uncovering the information you need to know to protect your health.

OPIOIDS